Literature DB >> 22677077

Positron emission tomographic scans in lymphoma: convention and controversy.

Stephen M Ansell1, James O Armitage.   

Abstract

The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma.
Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22677077      PMCID： PMC3498383          DOI： 10.1016/j.mayocp.2012.03.006

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


  65 in total

1.  Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  Andrew Wirth; John F Seymour; Rodney J Hicks; Robert Ware; Richard Fisher; Miles Prince; Michael P MacManus; Gail Ryan; Henry Januszewicz; Max Wolf
Journal:  Am J Med       Date:  2002-03       Impact factor: 4.965

2.  PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.

Authors:  Beatriz Rodríguez-Vigil; Nieves Gómez-León; Inmaculada Pinilla; Dolores Hernández-Maraver; Juan Coya; Luis Martín-Curto; Rosario Madero
Journal:  J Nucl Med       Date:  2006-10       Impact factor: 10.057

3.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis.

Authors:  Alfred Ian Lee; Dan S Zuckerman; Annick D Van den Abbeele; Suzanne L Aquino; Diane Crowley; Christiana Toomey; Ann S Lacasce; Yang Feng; Donna S Neuberg; Ephraim P Hochberg
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

6.  Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma.

Authors:  Martin Allen-Auerbach; Andrew Quon; Wolfgang A Weber; Sebastian Obrzut; Tyler Crawford; Daniel H S Silverman; Osman Ratib; Michael E Phelps; Johannes Czernin
Journal:  Mol Imaging Biol       Date:  2004 Nov-Dec       Impact factor: 3.488

7.  Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?

Authors:  Pierre Y Salaun; Thomas Gastinne; Caroline Bodet-Milin; Loïc Campion; Pierre Cambefort; Anne Moreau; Steven Le Gouill; Christian Berthou; Philippe Moreau; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-05       Impact factor: 9.236

8.  Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

Authors:  Niklaus G Schaefer; Thomas F Hany; Christian Taverna; Burkhardt Seifert; Katrin D M Stumpe; Gustav K von Schulthess; Gerhard W Goerres
Journal:  Radiology       Date:  2004-07-23       Impact factor: 11.105

Review 9.  2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.

Authors:  Lena Specht
Journal:  Semin Radiat Oncol       Date:  2007-07       Impact factor: 5.934

10.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

Authors:  K Spaepen; S Stroobants; P Dupont; P Vandenberghe; J Thomas; T de Groot; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976
View more
  19 in total

1.  Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.

Authors:  Silvia Morbelli; Selene Capitanio; Fabrizio De Carli; Francesca Bongioanni; Enrico De Astis; Maurizio Miglino; Maria Teresa Verardi; Ambra Buschiazzo; Francesco Fiz; Cecilia Marini; Elena Pomposelli; Gianmario Sambuceti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-19       Impact factor: 9.236

2.  Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome.

Authors:  C P Reinert; B Federmann; J Hofmann; H Bösmüller; S Wirths; J Fritz; M Horger
Journal:  Eur Radiol       Date:  2019-06-24       Impact factor: 5.315

3.  Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma.

Authors:  M Damlaj; S Ghazi; G Syed; T Pasha; G Gmati; H Salama; O Ali; K A Abuelgasim; M Al-Zahrani; A Hejazi; A Al Askar
Journal:  Bone Marrow Transplant       Date:  2017-07-10       Impact factor: 5.483

Review 4.  Updates on Circulating Tumor DNA Assessment in Lymphoma.

Authors:  Justin M Darrah; Alex F Herrera
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

5.  The Impact of 2-(18) Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in Treatment Strategy of Hodgkin Lymphoma-Current Hematologic Concepts.

Authors:  Oana Stanca; Anca Roxana Lupu; Anca Ciobanu; Irina Triantafyllidis
Journal:  Maedica (Buchar)       Date:  2015-06

6.  Fully automated radiosynthesis of 2-[18F]fludarabine for PET imaging of low-grade lymphoma.

Authors:  Stéphane Guillouet; Delphine Patin; Olivier Tirel; Jérôme Delamare; Fabienne Gourand; Jean Bernard Deloye; Michel Leporrier; Louisa Barré
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

7.  Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy.

Authors:  Raheleh Taghvaei; Mahdi Zirakchian Zadeh; Reza Sirous; Sara Pourhassan Shamchi; William Y Raynor; Siavash Mehdizadeh Seraj; Mateen Moghbel; Shiyu Wang; Thomas J Werner; Hongming Zhuang; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-12-20

8.  Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma.

Authors:  Shunan Qi; May Y Huang; Yong Yang; Heiko Schöder; Sewit Teckie; Ariela Noy; Karen Chau; Joachim Yahalom
Journal:  Blood Adv       Date:  2018-03-27

9.  Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Michael J Conte; Deborah A Bowen; Gregory A Wiseman; Kari G Rabe; Susan L Slager; Susan M Schwager; Timothy G Call; David S Viswanatha; Clive S Zent
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 10.  Managing lymphoma with non-FDG radiotracers: current clinical and preclinical applications.

Authors:  Fan-Lin Kong; Richard J Ford; David J Yang
Journal:  Biomed Res Int       Date:  2013-06-06       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.